Inhalation drug delivery devices and emerging technologies

Expert Opinion on Therapeutic Patents

Volumn 13, Issue 9, 2003, Pages 1333-1343

  Chan, Hak Kim ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Aerosol drug delivery; Aerosol inhalers; Atomisers; Dry powder inhalers (DPI); Inhalation formulation; Metered dose inhalers (MDI); Powder technology

Indexed keywords

ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE RECEPTOR STIMULATING AGENT; ALPHA 1 ANTITRYPSIN; ANTIASTHMATIC AGENT; ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; DEOXYRIBONUCLEASE; DOXORUBICIN; ERGOTAMINE; FLUTICASONE PROPIONATE; FORMOTEROL FUMARATE; GENTAMICIN; HUMAN GROWTH HORMONE; INSULIN; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEUPRORELIN; LIPOXYGENASE INHIBITOR; MOMETASONE FUROATE; MONTELUKAST; OXITROPIUM BROMIDE; PIRBUTEROL ACETATE; PROPELLANT; SALBUTAMOL SULFATE; SALMETEROL XINAFOATE; STEROID; TOBRAMYCIN; UNINDEXED DRUG; ZAFIRLUKAST;

AEROSOL; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CRYSTALLIZATION; CYSTIC FIBROSIS; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG INDUSTRY; DRY POWDER; EMPHYSEMA; ENDOMETRIOSIS; GROWTH HORMONE DEFICIENCY; HUMAN; INHALATION; LUNG CARCINOMA; LUNG INFECTION; METERED DOSE INHALER; MIGRAINE; NEBULIZER; POWDER INHALER; PROSTATE CANCER; REVIEW; TECHNOLOGY;

EID: 0141740310     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.13.9.1333     Document Type: Review

References (57)

1. BISGAARD HS, O'CALLAGHAN C, SMALDONE GC (Eds): Drug Delivery to the Lung. Marcel Dekker, Inc., New York, USA (2002).
2. MOREN F, DOLOVICH MB, NEWHOUSE MT et al. (Eds): Aerosols in Medicine: Principles, Diagnosis and Therapy. Elsevier Science Publishing, Amsterdam, The Netherlands (1993).
3. BARNES PJ, DRAZEN JM, RENNARD S et al. (Eds): Asthma and COPD: Basic Mechanisms and Clinical Management. Academic Press, London, UK (2002).
4. CHUNG KF, BARNES PJ: Mediator antagonists. In: Asthma and COPD: Basic Mechanisms and Clinical Management. Barnes PJ, Drazen JM, Rennard S et al. (Eds), Academic Press, London, UK (2002):565-571.
5. SMITH AL: Inhaled antibiotic therapy: what drug? what dose? what regimen? what formulation? J. Cystic Fibrosis (2002) 1:S189-S193.
6. CIPOLLA DC, CALRK AR, CHAN H-K et al.: Assessment of aerosol delivery systems for recombinant human deoxyribonuclease. STP Pharma Sciences (1994) 4:50-62.
7. MATHER LE, WOODHOUSE A, WARD ME et al.: Pulmonary administration of aerosolized fentanyl: pharmacokinetic analysis of a systemic delivery. Br. J. Clin. Pharmacol. (1998) 46:37-43.
8. DERSHWITZ M, WALSH JL, MORISHIGE RJ et al.: Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers. Anesthesiology (2000) 93:619-628.
9. WARD ME, WOODHOUSE A, MATHER LE et al.: Morphine pharmacokinetics after pulmonary administration from a novel aerosol delivery system. Clin. Pharmacol. Ther. (1997) 62:596-609.
10. SKYLER J, CEFALU W, KOURIDES I et al.: Efficacy of inhaled human insulin in Type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet (2001) 357:331-335.
11. CEFALU W, SKYLER J, KOURIDES I et al.: Insulin human insulin treatment in patients with Type 2 diabetes mellitus. Ann. Intern. Med. (2001) 134:203-207.
12. PERERA A, KAPITZA C, NOSEK L et al.: Absorption and metabolic effect of inhaled insulin. Diabetes Care (2002) 25:2276-2281.
13. CLARK AR: Medical aerosol inhalers: past, present and future. Aerosol Sci. Tech. (1995) 22:374-381.
14. MOHSEN NM: pMDI aerosol momentum manipulation and biotargeted delivery. In: Respiratory Drug Delivery VIII. Dalby RN, Byron PR, Peart J, Farr SJ (Eds), Davis Horwood International Publishing, Godalming/Surrey, USA (2002):593-597.
15. VERVAET C, BYRON P: Drug-surfactant-propellant interactions in HFA-formulations. Int. J. Pharm. (1999) 186:13-30.
16. KELLER M: Innovations and perspectives of metered-dose inhalers in pulmonary drug delivery. Int. J. Pharm. (1999) 186:81-90.
17. MEAKIN BJ, LEWIS DA, GANDERTON D et al.: Countering challenges posed by mimicry of DFD performance using HFA systems. In: Respiratory Drug Delivery VII. Dalby RN, Byron PR, Farr SJ, Peart J (Eds), Serentec Press, Raleigh, NC, USA (2000):99-107.
18. STFELY JS, BROWN B, HAMMERBECK DM et al.: Equipping the MDI for the 21st century by expanding its formulation options. In: Respiratory Drug Delivery VIII. Dalby RN, Byron PR, Peart J, Farr SJ (Eds), Davis Horwood International Publishing, Godalming/Surrey, USA (2002):207-213.
19. CHAN H-K, GONDA I: Development of systematic theory of suspension inhalation aerosols. II. Aggregates of monodisperse particles nebulised in polydisperse droplets. Int. J. Pharm. (1988) 41:147-157.
20. NEWHOUSE MT, HIRST PH, DUDDU SP et al.: Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest (2003) 124:360-366.
21. ANDERSON SD, BRANNAN JD, CHAN H-K: Use of aerosols for bronchial provocation testing in the laboratory: where we have been and where we are going. J. Aerosol. Med. (2002) 15:313-324.
22. DENYER J, PAVIA D, ZIERENBERG B: New liquid drug aerosol devices for inhalation therapy. Eur. Repir. Rev. (2000) 10:187-191.
23. KASTELIK JA, WRIGHT GA, AZIZ I et al.: A widely available method for the assessment of aerosol delivery in cystic fibrosis. Pulmon. Pharmacol. Ther. (2002) 15:513-519.
24. SOMMERER K, BRAND MP, MULLINGER B et al.: A strategy to optimize peripheral lung deposition in patients with emphysema. In: Respiratory Drug Delivery VIII. Dalby RN, Byron PR, Peart J, Farr SJ (Eds), Davis Horwood International Publishing, Godalming/Surrey, USA (2002):475-478.
25. YOSHIYAMA Y, YAZAKI T, ARAI M et al.: The nebulization of budesonide suspensions by a newly developed mesh nebulizer. In: Respiratory Drug Delivery VIII. Dalby RN, Byron PR, Peart J, Farr SJ (Eds), Davis Horwood International Publishing, Godalming/Surrey, USA (2002):487-489.
26. CIPOLLA D, FARR S, FIORE M et al.: AREx: synthesis of technologies to provide therapeutic benefits via pulmonary drug delivery. Polymer Preprints (1999) 40:326-327.
27. SIMON M, GOPALAKRISHNAN V: AeroDose™ inhaler - feasibility studies with the aerosol generator. In: Respiratory Drug Delivery VII. Dalby RN, Byron PR, Farr SJ, Peart J (Eds), Serentec Press, Raleigh, NC, USA (2000):311-314.
28. WISSINK JM, VAN RIJN CJM: Smart micromachined nozzles for monodisperse aerosol generation using low pressure Rayleigh break-up. In: Respiratory Drug Delivery VIII. Dalby RN, Byron PR, Peart J, Farr SJ (Eds), Davis Horwood International Publishing, Godalming/Surrey, USA (2002):509-512.
29. SMART J, BERG E, BERBRINK O et al.: TouchSpray™ technology: comparison of the droplet size measured with cascade impaction and laser diffraction. In: Respiratory Drug Delivery VIII. Dalby RN, Byron PR, Peart J, Farr SJ (Eds), Davis Horwood International Publishing, Godalming/Surrey, USA (2002):525-528.
30. GOODALL S, CHEW N, CHAN K et al.: Aerosolisation of protein solutions using thermal ink jet technologr. J. Aerosol Med. (2002)15:351-357.
31. ZIMLICH W, DING J, BUSICK D et al.: Development of multiple clinical and commercial applications using Mystic™ inhalation delivery technologies. In: Respiratory Drug Delivery VIII. Dalby RN, Byron PR, Peart J, Farr SJ (Eds), Davis Horwood International Publishing, Godalming/Surrey, USA (2002):363-366.
32. SPALLEK MW, HOCHRAINER D, WACHTEL H: Optimising nozzles for soft mist inhalers. In: Respiratory Drug Delivery VIII. Dalby RN, Byron PR, Peart J, Farr SJ (Eds), Davis Horwood International Publishing, Godalming/Surrey, USA (2002):375-378.
33. VILLAX P, BRITO V, STECKEL H: Development and performance of a new simple dry powder inhaler operating at low airflow rates. In: Respiratory Drug Delivery VIII. Dalby RN, Byron PR, Peart J, Farr SJ (Eds), Davis Horwood International Publishing, Godalming/Surrey. USA (2002):459-462.
34. LIGOTKE NW: Develoment and characterization of a dry powder inhaler. In: Respiratory Drug Delivery VIII. Dalby RN, Byron PR, Peart J, Farr SJ (Eds), Davis Horwood International Publishing, Godalming/Surrey, USA (2002):419-422.
35. CLARK AR, SHIRE SJ: In: Protein Formulation and Delivery. McNally EJ (Ed.) Marcel Dekker, Inc., New York, USA (2000):214-216.
36. LUCAS P, CLARKE MJ, ANDERSON M et al.: The role of fine particle excipients in pharmaceutical dry powder aerosols. In: Respiratory Drug Delivery VI. Dalby RN, Byron PR, Farr SJ (Eds), Interpharm Press, Il, USA (1996):243-250.
37. KELLER M, MULLER-WALZ R, GILCHRIST P et al.: Effect of storage on the in vitro performance of formoterol-fumarate powder blends in the SkyePharma MDPI. In: Respiratory Drug Delivery VII. Dalby RN, Byron PR, Farr SJ, Peart J (Eds), Serentec Press, Raleigh, NC, USA (2000):511-514.
38. LUCAS P, ANDERSON K, POTTER UJ et al.: Enhancement of small particle size drug powder aerosol formulations using an ultra low density additive. Pharm. Res. (1999) 16:1643-1647.
39. FULTS KA, MILLER IF, HICKEY AJ: Effect of particle morphology on emitted dose of fatty acid-treated disodium cromoglycate powder aerosols. Pharm. Dev. Technol. (1997) 2:67-79.
40. BYRON PR, PEART J, STANIFORTH JN: Aerosol electrostatics I: properties of fine powders before and after aerosolization by dry powder inhalers. Pharm. Res. (1997) 14:698-705.
41. CHAN H-K, CLARK A, GONDA I et al.: Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery. Pharm. Res. (1997) 14:431-437.
42. YAMASHITA C, NISHIBAYASHI T, AKASHI S et al.: A novel formulation of dry powder for inhalation of peptides and proteins. In: Respiratory Drug Delivery VI. Dalby RN, Byron PR, Farr SJ (Eds), Interpharm Press, Buffalo Grove, IL, USA (1996): 483-485.
43. CHEW NYK, CHAN H-K: Effect of amino acids on the dispersion of spray dried cromoglycate powders as aerosol. In: Respiratory Drug Delivery VIII. Dalby RN, Byron PR, Peart J, Farr SJ (Eds), Davis Horwood International Publishing, Godalming/Surrey, USA (2002):619-622.
44. MAA Y-F, NGUYEN P-A, SWEENEY T et al.: Protein inhalation powders: spray drying versus spray freeze drying. Pharm. Res. (1999) 16:249-254.
45. EDWARDS DA, HANES J, CAPONETTI G et al.: Large porous partides for pulmonary drug delivery. Science (1997) 276:1868-1871.
46. BOT AI, TARARA TE, SMITH DJ et al.: Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract. Pharm. Res. (2000) 17:275-283.
47. CHEW NYK, CHAN H-K: Use of solid corrugated particles to enhance powder aerosol performance. Pharm. Res. (2001) 18:1570-1577.
48. DUDDU SP, SISK SA, WALTER YH et al.: Improved lung delivery from a passive dry powder inhaler using an engineered PulmoSphere powder. Pharm. Res. (2002) 19:689-695.
49. OSTRANDER KD, HOVEY DC, KNAPP DA et al.: Potential delivery advantages of spray-dried Nanocrystals™ colloidal budesonide with the Clickhaler®. In: Respiratory Drug Delivery VII. Dalby RN, Byron PR, Farr SJ, Peart J (Eds), Serentec Press, Raleigh, NC, USA (2000 ):447-449.
50. MASTERS K: Spray Drying Handbook (3rd edn). Halsted Press, New York, USA (1979).
51. WATANABE W, AHONEN P, KAUPPINEN E et al.: Novel method for the synthesis of inhalable multicomponent drug powders with controlled morphology and size. In: Respiratory Drug Delivery VIII. Dalby RN, Byron PR, Peart J, Farr SJ (Eds), Davis Horwood International Publishing, Godalming/Surrey, USA (2002):795-797.
52. MAA YF, NGUYEN P-A, SWEENEY T et al.: Protein inhalation powders: spray drying versus spray freeze drying. Pharm. Res. (1999) 16:249-254.
53. CHEN JF, WANG YH, GUO F et al.: Synthesis of nanoparticles with nanotechnology: high-gravity reaction precipitation. Ind. Eng. Chem. Res. (2000) 39:948-954.
54. YORK P, HANNA M: Particle engineering by supercritical fluid technologies for powder inhalation drug delivery. In: Proceedings of Respiratory Drug Delivery VI. Dalby RN, Byron PR, Farr SJ (Eds), Interpharm Press, Buffalo Grove, IL, USA (1996):231-239.
55. SIEVERS RA, SELLERS SP, CLARK GS, VILLA JA, MIOSKOWSKI B, CARPENTER J: Supercritical fluid carbon dioxide technologies for fine particle formation for pulmonary drug delivery. 219th ACS National Meeting, San Francisco, CA, USA (March 2000):MSDI-173.
56. BUSTAMI RT, CHAN H-K, DEHGHANI F et al.: Recent application of supercritical fluid technology to pharmaceutical powder systems, Kona, powder and particle (2001) 19:57-70.
57. BUSTAMI RT, CHAN H-K, DEHGHANI F et al.: Generation of microparticles of proteins for aerosol delivery using high pressure modified carbon dioxide. Pharm. Res. (2000) 17:1360-1366.